

## DAFTAR PUSTAKA

- Ahmadi, S. 2008. *Faktor Risiko Kejadian Malaria di Desa Lubuk Nipis Kecamatan Tanjung Agung Kabupaten Muara Enim*. Tesis tidak diterbitkan. Semarang: Universitas Diponegoro.
- Aminake, M.N., Arndt, H-D., Pradel, G. 2012. *The Proteasome of Malaria Parasite: A Multi-stage Drug Target for Chemotherapeutic Intervention*. Germany : Elsevier Ltd.
- Baratawidjaja, K.G. 2006. Imunologi dasar. Edisi ke-7. Balai Penerbit FK UI, Jakarta: v + 572 hlm.
- Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, et al. 2003. *The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum*. *PLoS Biol* 1: E5.
- Brooks FB, Janet SB, Stephen AM. 2004. *Jawetz, Melnick, and Adelberg's Medical Microbiology 23<sup>rd</sup> Edition*. New York: The McGraw Hill Companies, Inc.
- Cowman, A.F., Galatis, D., and Thompson, J.K. 1994. *Selection for Mefloquine Resistance in Plasmodium falciparum is linked to Amplification of the pfmdr1 Gene and Cross-Resistance to Halofantrine and Quinine*. USA: Proc. Natl. Acad. Sci. 1994; 91: 1143–1147.
- Crompton, P.D., Pierce, S.K., Miller, L.H. 2010. *Advances and Challenges in Malaria Vaccine Development*. Maryland, USA.



Czesny, B., Goshu, S., Cook, J.L., Williamson, K.C. 2009. *The Proteasome Inhibitor Epoxomicin Has Potent Plasmodium falciparum Gametocidal Activity*. American Society for Microbiology.

David A.F, Roshenthal, Croft L.S, Brun R., Nwaka S. 2004. *Antimalarial Drug Discovery: Efficacy Model For Compound Screening*. Nature review drug Discovery 3: 509.

Delcros, JG, Baudy Floc'hM, Prigent,C, Arlot-Bonnemains,Y. 2003. *Proteasome Inhibitor as Therapeutic Agents: Current and Future Strategies*. Current Medicinal Chemistry, 10, 479-503.

Depkes RI, 2008. *Pedoman Penatalaksanaan Kasus Malaria di Indonesia*. Jakarta, Indonesia.

Depkes RI, 2011. *Epidemimologi Malaria Di Indonesia*. Jakarta, Indonesia.

Depkes RI, 2012. *Pengendalian Penyakit dan Penyehatan Lingkungan Tahun 2012*. Jakarta, Indonesia.

Garner, P., Graves, P.M. 2005. *The benefits of artemisinin combination therapy for malaria extend beyond the individual patient*. PLoS Med 2(4): e105.

Gao De-Li. 2000. Berat molekul Proteasome 20s pada Plasmodium.

Gillespie, S. dan Pearson, R.D. 2001. *Principles and Practice of Clinical Parasitology*. London: John Wiley and Sons Ltd.

Glickman M H, Maytal V. 2002. *Regulating the 26S proteasome*. Curr. Top. Microbiol. Immunol. 268:43–72.

Harijanto P.N. 2006. *Buku Ajar Ilmu Penyakit Dalam*. Jakarta: PIP FKUI: 1732-1744.

Harijanto P.N., Nugroho A., Gunawan A.C. 2009. *Malaria dari Molekuler ke Klinis*, Edisi 2, Penerbit Buku Kedokteran (EGC).

Hasibuan, A.I.S. 2010. *Tingkat Pengetahuan Masyarakat terhadap Penyakit Malaria di Kecamatan Batang Serangan Kabupaten Langkat Provinsi Sumatera Utara*. Karya tulis ilmiah tidak diterbitkan. Medan: Universitas Sumatra Utara, Indonesia.

Hedhli, N and Depre. C. 2009. *Proteasome inhibitors and cardiac cell growth*. University of Medicine and Dentistry of New Jersey, New Jersey Medical School.

Islamuddin. 2010. *Malaria dengan Kehamilan*. Subbagian Tropik dan Infeksi, Fakultas Kedokteran, Universitas Andalas, Padang, Sumatera Barat, Indonesia.

Karyana M, Burdarm L, Yeung S, Kenangalem E, Wariker N, Maristela R, Umana K G, Vemuri R, Okoseray M J, Penttininen P M, Ebsworth P, Sugiarto P, Anstey N M, Tjitra E, Price R N. 2008. *Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum*. *Malaria Journal*, 7;148.

Kim HS, Okuda Y, Begum K, Nagai Y, Wataya Y, Kimura, M, Huruta T. *Analysis of pfmdr1 Gene in Mefloquine Resistant Plasmodium falciparum*. *Nucleic acids Symp. Ser* 2001; 1: 231-232.

Kreindenweiss, A., Kremsner, P.G., Mordmuller, B. 2008. *Comprehensive Study of Proteasome Inhibitors Against Plasmodium falciparum Laboratory Strains and Field Isolates from Gabon*. University of Tübingen, Tübingen, Germany.

Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK. 2003. *Discovery of gene function by expression profiling of the malaria parasite life cycle*. *Science* 301: 1503–1508.

Ljungstrom I, Perlmann H, Schlichtherle M, Scherf A, Wahlgren M. 2004. *Methods In Malaria Research*. Malaria Research and Reference Reagent Resource Center (MR4) American Type Culture Collection 10801 University Boulevard, Manassas, VA 20110-2209.

Marsh, K. 2005. *Malaria, Molecular and Clinical Aspects : Clinical Features of Malaria*. KEMRI Centre for Geographic Medicine Research Coast, Kilifi, Kenya.

Martindale, 2009. *The Complete Drug Reference, 36th ed*. Sweetman SC, (ed). Pharmaceutical Press : 594-595.

McCutchan TF, Piper RC, Makler MT. 2008. *Use of malaria rapid diagnostic test to identify Plasmodium knowlesi infection*. *Emerg Infect Dis*. 2008;14: 1750–2.

Methods Mol Biol. 2005;295:227-54. *Immunoblotting techniques*. Magi B, LiberatoriS. Source Department of Molecular Biology, University of Siena, Siena, Italy.

Mueller I, Galinski MR, Baird JK, Carlton JM, Kocher DK, Alonso PL, Portillo HA. 2009. *Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite*. *The Lancet Infectious Diseases*: 555 – 566.

Mugittu K, Genton B, Mshinda H, and Beck HP. 2006. *Molecular Monitoring of Plasmodium falciparum resistance to Artemisinin in Tanzania*. *Malaria Journal* 5 (126).

Nishiyama Y, Okuda Y, Kim H, Huruta T, Kimura M & Wataya Y. 2004. *Genetic analysis of mefloquine-resistant mechanism of Plasmodium falciparum.*

Oxford University Press Nucleic Acids Symposium Series 2004; 48: 163-164.

Piwnica-Worms D, Piwnica-Worms H. 2007. *Mechanism of Proteasome-Mediated Processing of Proteins.*

Dissertation Faculty of Biology, Universitas Ludwig-Maximilians, Munchen.

Plowe CV. 2003. *Monitoring Antimalarial Drug Resistance: Making the Most of the Tools at Hand.* J. Exp. Biol; 206: 3745–3752.

Ponts N, Yang J, Chung D-WD, Prudhomme J, Girke T, et al. 2008. *Deciphering the Ubiquitin-Mediated Pathway in Apicomplexan Parasites: A Potential Strategy to Interfere with Parasite Virulence.* PLoS ONE 3 (6): e2386.

Prescott, L. M., Harley, J. P., & Klein, D. A. 1999. *Microbiology.* Fourth Edition. WCB McGraw-Hill, Boston.

Primm, Guide Polyclonal Antibodies Against Antigen supplied by customer.

Pritts T A, Hungness E S, Hershko DD, Robb B W, Sun X, Luo G J, Fischer J E., Wong H R, Hasselgren P O. 2002. *Proteasome inhibitors induce heat shock response and increase IL-6 expression in human intestinal epithelial cells.* Am. J. Physiol. Regul. Integr. Comp. Physiol 282:R1016–R1026

Riskesdas RI, 2010. *Riskesdas 2010: Malaria di Indonesia.* Tim penyakit menular dan Biomedis, SIMNAS VI, Jakarta, Indonesia.

Rivo YBN, Alkarimah A, Ramadhani NN, Cahyono AW, Laksmi DA, Winarsih S, Fitri, LE. 2013. *Metabolite Extract of Streptomyces hygroscopicus Hygroscopicus Inhibit the Growth of Plasmodium berghei through*

*Inhibition of Ubiquitin – Proteasome System. Tropical Biomedicine 30(2): 291–300.*

Rosenthal PJ., 2003. *Review Antimalarial drug discovery: old and new approaches. The Journal of Experimental Biology 206: 3735-3744.*

Saliba KJ, Folb PI, & Smith PJ. 1998. *Role for the Plasmodium falciparum Digestive vacuole in Chloroquine Resistance. Biochem Pharmacol; 56: 313–320.*

Simamora, D. & Fitri, L.E. 2007. *Antimalarial Drug Resistance: Mechanism And The Role Of Drug Combination In Preventing It. Jurnal Kedokteran Brawijaya, XXIII (2).*

Su X, Kirkman LA, Fujioka H, and Wellems TE. 1997. *Complex Polymorphisms in an approximately 330 kDa Protein are linked to Chloroquine - Resistant P. falciparum in Southeast Asia and Africa. Cell; 91: 593–603.*

Sudjadi. 2008. *Biotehnologi Kesehatan. Yogyakarta: Kanisius: 120.*

Sulistyaningsih Fitri, L.E., Löscher, T., Berens-Riha, N.. 2010. *Diagnostic Difficulties with Plasmodium knowlesi Infection in Humans Emerging Infectious Diseases • www.cdc.gov/eid • 16(6):1033-1034.*

Takimoto C H, Diggikar S. 2002. *Heat shock protein and proteasome targeting agents. Hematol. Oncol. Clin. North Am 16:1269–1285*

Timothy G Lilburn, Hong Cai, Zhan Zhou, Yufeng Wang. 2011. *Protease-Associated Cellular Networks in Malaria Parasite Plasmodium falciparum. Las Vegas, NV, USA.*

Vabulas R. M., Hartl F. U. 2005. *Protein synthesis upon acute nutrient restriction relies on proteasome function.* Science 310:1960–1963.

Velentzas PD, Velentzas AD, Mpakou VE, Papassideri IS, Stravopodis DJ, and Margaritis LH. 2011. Proteasome inhibition induces developmentally deregulated programs of apoptotic and autophagic cell death during *Drosophila melanogaster* oogenesis. *Cell Biol. Int.* 35:15–27.

White NJ. 2004. *Antimalarial Drug Resistance.* The Journal of Clin. Inves. 2004; 113: 1084-1092.

Winstanley P, Ward S, Snow R, Breckenridge A. 2004. *Therapy of *Falciparum Malaria* in Sub-Saharan Africa: from Molecule to Policy.* Am. Soc for Microbiol; 17(3): 612-637.

WHO, 2010. *Global Report on Antimalarial Drug Efficacy and Drug Resistance : 2000-2010.* Geneva, Switzerland.

WHO, 2010. *Guidelines for The Treatment of Malaria – 2<sup>nd</sup> Edition.* Geneva, Switzerland.

WHO/SEARO. 2011. *What is Malaria?* WHO Regional Office for South-East Asia, New Delhi, India.

WHO, 2012. *World Malaria Report 2012.* Geneva, Switzerland.

WHO, 2013. *World Malaria Report: 2013.* Geneva, Switzerland.

